Short Interest Update on Achillion Pharmaceuticals (ACHN)

Achillion Pharmaceuticals (ACHN) : 14 days before expiry, shorts in Achillion Pharmaceuticals (ACHN) have reduced from 14,269,412 on Jul 29, 2016, to 13,440,594 on August 15, 2016. On an average, 986,623 shares are traded on the exchange. The outstanding bearish positions are equal to 11.6% of the float. Short sellers have covered -828,818 shares, a reduction of -5.8%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.

Achillion Pharmaceuticals (NASDAQ:ACHN): The stock opened at $9.17 on Wednesday but the bulls could not build on the opening and the stock topped out at $9.50 for the day. The stock traded down to $8.60 during the day, due to lack of any buying support eventually closed down at $8.60 with a loss of -6.72% for the day. The stock had closed at $9.22 on the previous day. The total traded volume was 2,584,814 shares.


In a related news,The officer (Chief Financial Officer) of Achillion Pharmaceuticals Inc, Fenton Mary Kay sold 43,500 shares at $10.08 on December 28, 2015. The Insider selling transaction had a total value worth of $438,480. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *